Department of Physiology, Orthopedics, Diabetic Unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
Vaccinations are highly essential to control infectious diseases and epidemics. Presently, the entire world faces a challenging crisis of "Severe Acute Respiratory Diseases Coronavirus 2 (SARS-CoV-2), also known as the COVID-19 pandemic". The impact of vaccines at national levels to reduce the SARS-CoV-2 cases and deaths are unclear, and people have concerns about the effectiveness of vaccines in real-world settings. This study's objective was to examine the effect of the "Pfizer/BioNTech and Oxford/AstraZeneca" vaccines to prevent SARS-CoV-2 cases and deaths in Saudi Arabia.
In this retrospective cohort study, we collected data on SARS-CoV-2 cases and deaths from the date of the first case of SARS-CoV-2 in Saudi Arabia March 2, 2020, to the date of launching the vaccination campaign on December 14, 2020; and from December 15, 2020, to September 8, 2021. We recorded the World Health Organization data and Ministry of Health of Saudi Arabia to evaluate the impact of the "Pfizer/BioNTech, (BNT162b2 mRNA) and Oxford/AstraZeneca (AZD1222)" vaccine against SARS-CoV-2 cases and deaths before and after the vaccination campaign in Saudi Arabia.
Saudi Arabia launched the "Pfizer/BioNTech and Oxford/AstraZeneca" vaccination campaign against SARS-CoV-2 on December 14, 2020. In Saudi Arabia, before the vaccination campaign from March 2, 2020, to December 14, 2020, the mean daily SARS-CoV-2 cases were 1235.60, daily deaths were 22.70, that significantly reduced (p=0.0001) compared to the period after the vaccination campaign from December 15, 2020, to September 8, 2021, in which the daily cases fell to 692.08, and daily deaths fell to 9.48 (p=0.0001).
In Saudi Arabia, Pfizer/BioNTech and Oxford/AstraZeneca vaccinations significantly reduced the number of SARS-CoV-2 cases and deaths after the vaccination compared to the period before the vaccination campaign at country levels. The study findings demonstrate that vaccination and adherence to nonpharmaceutical intervention can better control the COVID-19 pandemic.
接种疫苗对于控制传染病和流行病至关重要。目前,全世界都面临着“严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2),也称为 COVID-19 大流行”的严峻挑战。疫苗在国家层面上减少 SARS-CoV-2 病例和死亡的效果尚不清楚,人们对疫苗在真实环境中的效果存在担忧。本研究的目的是检验辉瑞/生物技术和牛津/阿斯利康疫苗在沙特阿拉伯预防 SARS-CoV-2 病例和死亡的效果。
在这项回顾性队列研究中,我们从 2020 年 3 月 2 日沙特阿拉伯首例 SARS-CoV-2 病例开始,到 2020 年 12 月 14 日疫苗接种运动开始,以及从 2020 年 12 月 15 日至 2021 年 9 月 8 日,收集了 SARS-CoV-2 病例和死亡数据。我们记录了世界卫生组织和沙特阿拉伯卫生部的数据,以评估在沙特阿拉伯接种疫苗运动前后辉瑞/生物技术(BNT162b2 mRNA)和牛津/阿斯利康(AZD1222)疫苗对 SARS-CoV-2 病例和死亡的影响。
沙特阿拉伯于 2020 年 12 月 14 日开始针对 SARS-CoV-2 开展辉瑞/生物技术和牛津/阿斯利康疫苗接种运动。在沙特阿拉伯,在 2020 年 12 月 14 日之前的疫苗接种运动之前,从 2020 年 3 月 2 日至 2020 年 12 月 14 日,每日 SARS-CoV-2 病例数为 1235.60,每日死亡数为 22.70,与疫苗接种运动之后相比显著降低(p=0.0001),即从 2020 年 12 月 15 日至 2021 年 9 月 8 日,每日病例数下降至 692.08,每日死亡数下降至 9.48(p=0.0001)。
在沙特阿拉伯,辉瑞/生物技术和牛津/阿斯利康疫苗接种在接种疫苗后与接种疫苗前相比,显著降低了 SARS-CoV-2 病例和死亡的数量。研究结果表明,接种疫苗和坚持非药物干预措施可以更好地控制 COVID-19 大流行。